Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
NCT07081022Phase 2Active, not recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Apr 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of JS203 in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Aug 2025; status: active, not recruiting.
02
Drugs
JS203
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT07081022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07081022.